Alix E Seif

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. ncbi Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis
    Alix E Seif
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Cancer Genet 204:227-44. 2011
  2. ncbi Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature
    Alix E Seif
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Pediatr Hematol Oncol 32:e349-52. 2010
  3. ncbi Secondary adrenal insufficiency in an infant after intrathecal triple chemotherapy
    Alix E Seif
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 55:386-9. 2010
  4. ncbi Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling
    David M Barrett
    Department of Pediatrics, Division of Oncology, Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Blood 118:e112-7. 2011
  5. ncbi Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease
    Valerie I Brown
    Division of Oncology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA, 19104, USA
    Immunol Res 42:84-105. 2008
  6. ncbi Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
    Shannon L Maude
    Division of Oncology, The Children s Hospital of Philadelphia, PA, USA
    Blood 120:3510-8. 2012
  7. ncbi Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses
    Alix E Seif
    Children s Hospital of Philadelphia, PA, USA
    Blood 114:2459-66. 2009
  8. ncbi Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)
    David T Teachey
    Children s Hospital of Philadelphia, University of Pennsylvania, 19104, USA
    Br J Haematol 148:205-16. 2010
  9. ncbi Targeting Notch signaling in autoimmune and lymphoproliferative disease
    David T Teachey
    Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine 19104, USA
    Blood 111:705-14. 2008
  10. ncbi Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study
    Alix E Seif
    Division of Hematology, Department of Pediatrics, Children s Hospital of Philadelphia, PA 19104, USA
    Blood 115:2142-5. 2010

Collaborators

Detail Information

Publications13

  1. ncbi Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis
    Alix E Seif
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Cancer Genet 204:227-44. 2011
    ....
  2. ncbi Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature
    Alix E Seif
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Pediatr Hematol Oncol 32:e349-52. 2010
    ..Combined with other pediatric reports, our experience supports the efficacy of ITlipAC in pediatric and infant leukemic meningitis...
  3. ncbi Secondary adrenal insufficiency in an infant after intrathecal triple chemotherapy
    Alix E Seif
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 55:386-9. 2010
    ..As multiple pediatric leukemia protocols incorporate ITT, particularly in infants, we feel that ITT should be considered as a potential source of adrenal axis suppression...
  4. ncbi Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling
    David M Barrett
    Department of Pediatrics, Division of Oncology, Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Blood 118:e112-7. 2011
    ....
  5. ncbi Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease
    Valerie I Brown
    Division of Oncology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA, 19104, USA
    Immunol Res 42:84-105. 2008
    ....
  6. ncbi Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
    Shannon L Maude
    Division of Oncology, The Children s Hospital of Philadelphia, PA, USA
    Blood 120:3510-8. 2012
    ....
  7. ncbi Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses
    Alix E Seif
    Children s Hospital of Philadelphia, PA, USA
    Blood 114:2459-66. 2009
    ..To our knowledge, this is the first demonstration that CpG ODN induce a durable remission and ongoing immune-mediated protection in ALL, suggesting this treatment may have clinical utility in patients with minimal residual disease...
  8. ncbi Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)
    David T Teachey
    Children s Hospital of Philadelphia, University of Pennsylvania, 19104, USA
    Br J Haematol 148:205-16. 2010
    ..This review describes the clinical and laboratory manifestations found in ALPS patients, as well as the molecular basis for the disease and new advances in treatment...
  9. ncbi Targeting Notch signaling in autoimmune and lymphoproliferative disease
    David T Teachey
    Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine 19104, USA
    Blood 111:705-14. 2008
    ..Inhibiting the Notch signaling pathway may thus present an effective, novel, and well-tolerated treatment for autoimmune and lymphoproliferative diseases...
  10. ncbi Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study
    Alix E Seif
    Division of Hematology, Department of Pediatrics, Children s Hospital of Philadelphia, PA 19104, USA
    Blood 115:2142-5. 2010
    ..This is the largest published series describing children with ES and documents a high rate of ALPS among pediatric ES patients. These data suggest that children with ES should be screened for ALPS with DNTs...
  11. ncbi Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma
    Leah A Commander
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Br J Haematol 150:345-51. 2010
    ..Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored...
  12. ncbi mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
    David T Teachey
    Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, PA 19104, USA
    Blood 112:2020-3. 2008
    ..We found methotrexate and MTIs are an effective and potentially synergistic combination in ALL...
  13. ncbi Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database
    Dana M Walker
    Division of Oncology, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 60:616-20. 2013
    ....